Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis

被引:4
作者
Kim, Seihee [1 ]
Chung, Yoon-Sok [2 ,3 ]
Lee, Yunhwan [3 ,4 ]
机构
[1] Ajou Univ, Grad Sch, Dept Med Sci, Suwon, South Korea
[2] Ajou Univ, Dept Endocrinol & Metab, Sch Med, Suwon, South Korea
[3] Ajou Univ, Inst Aging, Med Ctr, Suwon, South Korea
[4] Ajou Univ, Dept Prevent Med & Publ Hlth, Sch Med, 164 Worldcup Ro, Suwon 16499, South Korea
关键词
Osteoporosis; Medication adherence; Diphosphonates; POSTMENOPAUSAL WOMEN; DOSING FREQUENCY; UNITED-STATES; HIP FRACTURE; PERSISTENCE; THERAPY; HEALTH; IMPACT; NONCOMPLIANCE; REGIMENS;
D O I
10.1016/j.afos.2022.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort. We aim to evaluate whether adherence to bisphosphonate affects the risk of fracture in osteoporosis patients. Methods: We used the data of the Korean National Health Insurance Service Senior Cohort. A total of 33,315 (medication possession ratio [MPR]: 50) osteoporosis patients were matched using the propensity score matching method: those who received low-dose bisphosphonate and those who received highdose bisphosphonate. Twenty-two confounding variables, including age, socioeconomic status, medications prescribed, and underlying diseases that may affect the risk of fracture were adjusted for propensity score matching. The risk of vertebral fracture was assessed by Cox proportional hazards regression. Results: Patients with a higher MPR showed a decreased vertebral fracture risk than those with a lower MPR (MPR 50 = hazard ratio [HR] 0.909; 95% confidence interval [CI] 0.877e0.942 P < 0.001; MPR 70 = HR: 0.874, 95% CI: 0.838-0.913, P < 0.001; MPR 90 = HR: 0.822, 95% CI: 0.780-0.866, P < 0.001). MPR was associated with a decreased vertebral fracture risk in both groups with or without history of fracture. In the subgroup analysis, MPR was associated with a decreased vertebral fracture risk in women, in all ages, with or without T2DM, and with or without hypertension. Conclusions: Higher MPR is associated with a lower vertebral fracture risk. (c) 2022 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 30 条
[1]   Loss of treatment benefit due to low compliance with bisphosphonate therapy [J].
Beest, F. J. A. Penning-van ;
Erkens, J. A. ;
Olson, M. ;
Herings, R. M. C. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :511-517
[2]   Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women [J].
Blouin, Julie ;
Dragomir, Alice ;
Moride, Yola ;
Ste-Marie, Louis-Georges ;
Fernandes, Julio Cesar ;
Perreault, Sylvie .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (01) :117-127
[3]   The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases [J].
Brankin, Eamonn ;
Walker, Mel ;
Lynch, Niall ;
Aspray, Terence ;
Lis, Yvonne ;
Cowell, Warren .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (07) :1249-1256
[4]   Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 [J].
Burge, Russel ;
Dawson-Hughes, Bess ;
Solomon, Daniel H. ;
Wong, John B. ;
King, Alison ;
Tosteson, Anna .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (03) :465-475
[5]   Differences in Adherence to Osteoporosis Regimens: A 2-Year Analysis of a Population Treated Under Specific Guidelines [J].
Cheng, Tien-Tsai ;
Yu, Shan-Fu ;
Hsu, Chung-Yuan ;
Chen, Sung-Hsiung ;
Su, Ben Yu-Jih ;
Yang, Tsong-Shing .
CLINICAL THERAPEUTICS, 2013, 35 (07) :1005-1015
[6]   Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis [J].
Cotte, F. -E. ;
Fardellone, P. ;
Mercier, F. ;
Gaudin, A. -F. ;
Roux, C. .
OSTEOPOROSIS INTERNATIONAL, 2010, 21 (01) :145-155
[7]   A systematic review of persistence and compliance with bisphosphonates for osteoporosis [J].
Cramer, J. A. ;
Gold, D. T. ;
Silverman, S. L. ;
Lewiecki, E. M. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (08) :1023-1031
[8]   Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis [J].
Cramer, JA ;
Amonkar, MM ;
Hebborn, A ;
Altman, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) :1453-1460
[9]   The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France [J].
Cramer, Joyce A. ;
Lynch, Niall O. ;
Gaudin, Anne-Francoise ;
Walker, Mel ;
Cowell, Warren .
CLINICAL THERAPEUTICS, 2006, 28 (10) :1686-1694
[10]   Uptake of treatment for osteoporosis and compliance after bone density measurement in the community [J].
Dugard, M-N ;
Jones, T. J. ;
Davie, M. W. J. .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2010, 64 (06) :518-522